What is Dianthus Therapeutics's deferred revenue?

Dianthus Therapeutics (DNTH) reported deferred revenue of $849K in Q1 2026.

How has Dianthus Therapeutics's deferred revenue changed year-over-year?

Dianthus Therapeutics's deferred revenue increased by 1589.5% year-over-year, from -$57K to $849K.

What is the long-term trend for Dianthus Therapeutics's deferred revenue?

Over 2 years (2022 to 2024), Dianthus Therapeutics's deferred revenue has grown at a 63.7% compound annual growth rate (CAGR), from $891K to $2.39M.

Dianthus Therapeutics DNTH Deferred Revenue

Deferred Revenue at other companies

TG TherapeuticsTGTX

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Balance sheet

See full

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Cash flow

See full

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Valuation

See full

Market cap$4.51B+662%

Profitability

See full

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Returns & leverage

See full

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dianthus Therapeutics's deferred revenue?: Dianthus Therapeutics (DNTH) reported deferred revenue of $849K in Q1 2026.
How has Dianthus Therapeutics's deferred revenue changed year-over-year?: Dianthus Therapeutics's deferred revenue increased by 1589.5% year-over-year, from -$57K to $849K.
What is the long-term trend for Dianthus Therapeutics's deferred revenue?: Over 2 years (2022 to 2024), Dianthus Therapeutics's deferred revenue has grown at a 63.7% compound annual growth rate (CAGR), from $891K to $2.39M.